Persistent oxidative stress and inflammasome activation in CD14^{high}CD16⁺ monocytes from COVID-19 patients

Silvia Lucena Lage^{1*§}, Eduardo Pinheiro Amaral^{2*§}, Kerry L. Hilligan^{2,3}, Elizabeth Laidlaw¹, Adam Rupert⁴, Sivaranjani Namasivayan², Joseph Rocco¹, Frances Galindo¹, Anela Kellogg⁵, Princy Kumar⁶, Rita Poon⁶, Glenn W. Wortmann⁷, John P. Shannon⁸, Heather D. Hickman⁸, Andrea Lisco¹, Maura Manion¹, Alan Sher², Irini Sereti¹

¹HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

²Immunobiology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

³Immune Cell Biology Programme, Malaghan Institute of Medical Research, Wellington 6012, New Zealand.

⁴AIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD, USA.

⁵Clinical Monitoring Research Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, MD, USA.

⁶Division of Infectious Diseases and Travel Medicine at MedStar Georgetown University Hospital, Washington DC, USA.

⁷Section of Infectious Diseases, MedStar Washington Hospital Center, Washington, DC, USA.

1 ⁸Viral Immunity and Pathogenesis Unit, Laboratory of Clinical Immunology
2 and Microbiology, National Institutes of Allergy and Infectious Diseases,
3 National Institutes of Health, Bethesda, MD, USA.

4

5 **Running title:** Oxidative stress-associated inflammasome activation in
6 COVID-19.

7

8 ***Corresponding authors**

9 Silvia Lucena Lage, PhD

10 Email: silvia.lage@nih.gov

11 Telephone number: 240-669-5508

12 10 Center Drive, Bldg.10, Room 11B15, Bethesda MD, 20892

13

14 Eduardo Pinheiro Amaral, PhD

15 Email: eduardo.amaral@nih.gov

16 Telephone number: 301.761.7400

17 33 North Dr, Room 1W10A, Bethesda MD, 20892

18

19 [§] **These authors contributed equally to this work.**

20

21

ABSTRACT

The poor outcome of the coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, is associated with systemic hyperinflammatory response and immunopathology. Although inflammasome and oxidative stress have independently been implicated in COVID-19, it is poorly understood whether these two pathways cooperatively contribute to disease severity. Herein, we found an enrichment of CD14^{high}CD16⁻ monocytes displaying inflammasome activation evidenced by caspase-1/ASC-speck formation in severe COVID-19 patients when compared to mild ones and healthy controls, respectively. Those cells also showed aberrant levels of mitochondrial superoxide (MitoSOX) and lipid peroxidation, both hallmarks of the oxidative stress response, which strongly correlated with caspase-1 activity. In addition, we found that NLRP3 inflammasome-derived IL-1 β secretion by SARS-CoV-2-exposed monocytes *in vitro* was partially dependent on lipid peroxidation. Importantly, altered inflammasome and stress responses persisted after short-term patient recovery. Collectively, our findings suggest oxidative stress/NLRP3 signaling pathway as a potential target for host-directed therapy to mitigate early COVID-19 hyperinflammation as well as its long-term outcomes.

Keywords: COVID-19, NLRP3 inflammasome, Oxidative stress, Lipid peroxidation, CD14^{high}CD16⁻ monocytes.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), emerged in late 2019 and rapidly spread worldwide, leading to approximately 3.6 million deaths to date (WHO, 2021). Although the majority of infected individuals are asymptomatic or experience mild disease, about 20% of patients with COVID-19 develop moderate/severe manifestations mainly characterized by hypoxia and extensive pneumonia (Wu et al., 2020). Patients occasionally progress to critical condition as a result of pathological complications related to acute respiratory distress syndrome (ARDS), endothelial dysfunction and coagulopathy, leading to multi-organ failure and consequently death (Ackermann et al., 2020; Bonaventura et al., 2021; Dandel, 2021; Gibson et al., 2020).

Although the factors involved in disease progression to severe forms remain poorly understood, an exacerbated inflammatory response has been implicated as a major cause of morbidity and mortality in patients with COVID-19 (Hojyo et al., 2020; Tang et al., 2020). Overall, elevated levels of circulating inflammatory markers including C-reactive protein (CRP), ferritin, D-dimer and a wide range of inflammatory cytokines/chemokines have been associated with poor disease outcome. Importantly, the pro-inflammatory cytokines IL-1 β and IL-18 have both been implicated in lung injury and respiratory distress induced by SARS-CoV-2 (Conti et al., 2020; Meduri et al., 1995; Satis et al., 2021). Of note, mature IL-1 β plays an important role in immune cell recruitment to the site of infection as well as in stimulating cells to produce and release a number of inflammatory mediators including IL-6 and

1 CRP (Patton et al., 1995; Slaats et al., 2016). In addition, mature IL-18 has
2 also been associated with hyperferritinemia and cytopenias, both pathological
3 features observed in COVID-19 patients displaying severe disease
4 (Agbuduwe and Basu, 2020; Perricone et al., 2020).

5 IL-1 β and IL-18 production rely on inflammasome activation upon
6 sensing of pathogen/damage-associated molecular patterns (PAMPs/DAMPs)
7 by distinct innate immune intracellular sensors (Martinon et al., 2002; Sharma
8 and Kanneganti, 2016). Once activated, those sensors recruit the adapter
9 molecule ASC (apoptosis-associated speck-like protein containing a caspase
10 activating and recruitment domain, CARD) in order to activate pro-caspase-1,
11 thus forming the inflammasome complex also known as ASC-speck (Lu et al.,
12 2014). The enzymatic activity of caspase-1 is required for IL-1 β and IL-18
13 processing and secretion as well as for the cleavage of the pore-forming
14 protein gasdermin D (GSDMD), thus inducing a cell death process called
15 pyroptosis (Broz et al., 2010; Shi et al., 2015).

16 Among the distinct cytosolic sensors able to form inflammasomes the
17 molecule NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) has
18 been implicated in COVID-19 (Abais et al., 2015; Freeman and Swartz, 2020;
19 Rodrigues et al., 2021; Shah, 2020). Several stress-related cellular processes
20 have been reported to induce NLRP3 activation in response to distinct PAMPs
21 and DAMPs, such as K⁺ efflux (Munoz-Planillo et al., 2013), lysosomal
22 disruption (Hornung et al., 2008), mitochondrial damage (Iyer et al., 2013;
23 Zhou et al., 2011) and the generation of reactive oxygen species (ROS)
24 (Martinon, 2010; Tschopp and Schroder, 2010). Since robust redox responses
25 observed in hypoxic conditions during other pulmonary infections are

1 commonly associated with exacerbated cytokine production and disease
2 progression (Amaral et al., 2021; Erlich et al., 2020; Favier et al., 1994;
3 Freeborn and Rockwell, 2021; Pohanka, 2013; Prabhakar et al., 2020), host
4 oxidative stress has also been implicated in the pathogenesis of COVID-19
5 (Delgado-Roche and Mesta, 2020; Fakhri et al., 2020; Ntyonga-Pono, 2020).

6 Oxidative stress results from the imbalance of total oxidant status over
7 antioxidant response (Bhat et al., 2012). Aberrant generation of ROS along
8 with accumulation of toxic lipid peroxides can be detrimental to host cells and
9 thus promote tissue damage. The inability of cells to detoxify biological
10 membranes from lipid peroxidation is caused by a decrease in the enzymatic
11 activity of glutathione peroxidase-4 (Gpx4) often due to reduced intracellular
12 levels of its co-factor glutathione (GSH). Of note, a decrease in GSH levels
13 has been reported in several comorbidities including type-2 diabetes
14 (Goutzourelas et al., 2018; Lutchmansingh et al., 2018; Sekhar et al., 2011;
15 Tan et al., 2012), obesity, cardiovascular disorders (Cavalca et al., 2009;
16 Chaves et al., 2007; Shimizu et al., 2004), respiratory diseases (Fitzpatrick et
17 al., 2012; Fitzpatrick et al., 2011; Fitzpatrick et al., 2009; Rahman and
18 MacNee, 1999) cancer (Balendiran et al., 2004; Traverso et al., 2013) and
19 hepatitis (Burgunder and Lauterburg, 1987; Shaw et al., 1983), most of which
20 have been recognized as risk factors for the severe outcome of COVID-19.
21 Moreover, it is possible that uncontrolled oxidative stress in the lung may form
22 a positive feedback loop exacerbating NLRP3-inflammasome activation the
23 production of pro-inflammatory cytokines such as IL-1 β . In addition, the
24 dysregulation of the cellular antioxidant response controlling lipid peroxidation
25 may represent a potential host factor to be targeted to prevent aberrant

1 inflammatory responses. However, the possible interplay of these two
2 important inflammatory responses has not been formally investigated at the
3 cellular level in COVID-19 patients.

4 Here, we assessed inflammasome and oxidative stress activation in
5 circulating blood monocytes from COVID-19 patients and investigated
6 whether these cellular pathways cooperatively contribute to COVID-19
7 disease severity and cytokine release syndrome. Our findings provide insights
8 into the pathogenesis of COVID-19, both during acute infection and early
9 recovery, suggesting inhibition of both NLRP3-inflammasome activation and
10 lipid peroxidation as potential therapeutic interventions in COVID-19.

11

RESULTS

Significant changes in circulating monocyte subsets in COVID-19 patients

Dysregulated activation of the mononuclear phagocyte compartment leads to pathological inflammation and has been implicated in COVID-19 severity (Merad and Martin, 2020). We first investigated phenotypic changes in circulating blood monocytes from healthy control individuals (HCs) and COVID-19 patients experiencing mild or moderate-severe disease. Patients enrolled in this study were classified according to their oxygen requirement at the time of the research blood draw as (1) mild for patients requiring less than 4 Liters of oxygen (including no oxygen needed) (n=31; 23 inpatients and 8 outpatients, respectively), (2) moderate (n=4) for subjects who required up to 50% oxygen concentration, and (3) severe (n=12) for patients with a fraction of inspired oxygen (FiO₂) over 50% or admitted to ICU care. We pooled patients displaying moderate and severe forms of the disease in the same group, which we named moderate-severe. Two patients remain in the critical care unit and one participant died by the time the study was completed. In addition, 14 patients were followed longitudinally after a short-term recovery period (approximately 52 days after infection onset), and 2 subjects were recruited after recovery. Clinical and demographic features of patients enrolled in the study are summarized in **Table 1**.

We observed that COVID-19 patients displayed a striking depletion of the patrolling CD14^{low}CD16⁺ subset (Figure 1A-B) accompanied by enrichment of the CD14^{high}CD16⁻ classical/inflammatory monocytes compared

1 to HCs (Figure 1A and 1C). Moreover, CD14^{high}CD16⁻ classical monocytes
 2 from COVID-19 patients showed downmodulation of HLA-DR and of the C–C
 3 chemokine receptor type 2 (CCR2) (Figure 1D and 1E, respectively).
 4 However, none of these features were associated with disease severity, since
 5 similar frequency of monocyte subsets and surface markers were observed
 6 when COVID-19 patients were grouped in mild and moderate-severe disease
 7 categories (Figure 1F-I). Collectively, these results demonstrate phenotypical
 8 and proportional changes in the peripheral monocytic compartment during
 9 SARS-CoV-2 infection consistent with previous reports (Wilk et al., 2020;
 10 Zhou et al., 2021)

11 **Systemic inflammasome activation during COVID-19 is associated with** 12 **disease severity**

13 Systemic inflammation has been considered as a hallmark of COVID-
 14 19 severity (Hojyo et al., 2020). Accordingly, several molecular measurements
 15 associated with systemic inflammation including CRP, D-dimers, ferritin and
 16 IL-6 were elevated in plasma from COVID-19 patients in our cohort (Table 2
 17 and Supplemental Figure 1). Additional analysis of these inflammatory
 18 markers failed to discriminate disease severity in this patient cohort
 19 (Supplemental Table 1). It is important to highlight that the COVID-19 patients
 20 were enrolled in the mild group based on their lower oxygen requirement
 21 (nasal cannula 4 Liters or less or no oxygen), which differs from other studies
 22 where only outpatients displaying no oxygen requirement were assigned as
 23 mild patients.

24 In addition to the above mentioned inflammatory markers, the

1 inflammasome-derived cytokine IL-18 has also been implicated in COVID-19-
 2 associated pathological inflammation (Conti et al., 2020; Meduri et al., 1995;
 3 Satis et al., 2021). Accordingly, we observed higher plasma levels of IL-18 in
 4 our cohort of COVID-19 patients when compared to HCs (Figure 2A),
 5 suggesting systemic inflammasome activation in this group of patients. Since
 6 drastic depletion of the patrolling monocytes subset along with increased
 7 levels of classical/inflammatory CD14^{high}CD16⁻ monocytes were observed in
 8 COVID-19 patients, we evaluated whether CD14^{high}CD16⁻ cells represent a
 9 source of inflammasome activation during COVID-19. To do so, peripheral
 10 blood mononuclear cells (PBMCs) from HCs and patients were incubated with
 11 FLICA, an approach widely used to measure caspase-1/4/5 activity. We
 12 observed higher caspase-1/4/5 activity within the classical monocyte subset
 13 from COVID-19 patients when compared to HCs (Figure 2B), suggesting this
 14 cell subset contributes to IL-1 β and IL-18 maturation during COVID-19.

15 To directly evaluate inflammasome complex formation in
 16 CD14^{high}CD16⁻ monocytes, we screened classical monocytes from HCs and
 17 COVID-19 patients for active ASC aggregates by imaging flow cytometry,
 18 following a previously described protocol (Lage et al., 2019). Briefly, PBMCs
 19 were pre-incubated with FLICA for caspase-1 detection followed by
 20 immunophenotyping and intracellular ASC staining. Using this approach, we
 21 identified monocytes with cytosolic ASC speck formation associated with
 22 active caspase-1/4/5, represented by FLICA⁺ASC-speck⁺ cells (Figure 2C,
 23 Merge panel). The summary data in Figure 2D demonstrate a substantially
 24 higher frequency of classical monocytes showing FLICA⁺ASC-speck⁺
 25 formation in COVID-19 patients than HC subjects, which positively correlated

1 with plasma IL-18 levels (Figure 2E). Importantly, in contrast to the other
2 plasma inflammatory markers tested in this study (Supplemental Table 1), the
3 percentage of monocytes with inflammasome complex formation and plasma
4 levels of the downstream cytokine IL-18 were both significantly increased in
5 the moderate-severe group than in patients with milder symptoms (Figure 2F
6 and 2G, respectively), highlighting a role for inflammasomes in COVID-19
7 severity. Of note, inflammasome activation in circulating classical monocytes
8 was not associated with age, sex, BMI, or race in our group of patients
9 (Supplemental Figure 2).

10 Consistent with systemic inflammation, COVID-19-derived PBMCs but
11 not HC cells spontaneously released IL-1 β , as well as IL-6 and TNF- α *ex vivo*
12 (Figure 3A, 3B and 3C, respectively). We next tested the effect of MCC950, a
13 specific inhibitor of the NLRP3 inflammasome, and colchicine, an anti-
14 inflammatory compound, on spontaneous cytokine release from COVID-19
15 patient cells. In addition to other anti-inflammatory effects, colchicine has
16 been shown to inhibit microtubule-driven spatial arrangement of mitochondria,
17 thus preventing full NLRP3 inflammasome activation (Misawa et al., 2013)
18 and its use has been also reported to have beneficial effects in outpatients but
19 not in hospitalized COVID-19 patients in recent clinical trials (Horby et al.,
20 2021; Lopes et al., 2021; Tardif et al., 2021). Despite the promising clinical
21 use of colchicine to prevent inflammasome activation, we did not observe any
22 effect of compound on cytokine release by patient-derived PBMCs *in vitro*
23 (Figure 3D-F). Conversely, selective inhibition of the inflammasome sensor
24 NLRP3 by MCC950 specifically abolished IL-1 β secretion *ex vivo* by PBMCs
25 from COVID-19 patients without impacting IL-6 and TNF- α production (Figure

3D, 3E and 3F, respectively). Collectively, our findings support a role for NLRP3-mediated ASC-speck formation and caspase-1 activation in pathologic inflammation associated with moderate and severe forms of COVID-19.

CD14^{high}CD16⁻ monocytes from COVID-19 patients exhibit prominent oxidative stress activity

Oxidative stress has been suggested to be a critical host factor in driving immune response exacerbation in several infectious diseases (Amaral et al., 2021; Erlich et al., 2020; Favier et al., 1994; Freeborn and Rockwell, 2021; Pohanka, 2013). However, the induction of inflammatory oxidative stress responses in circulating monocytes obtained from COVID-19 patients has not been formally investigated. First, we sought to investigate the systemic oxidative response in plasma obtained from our cohort of COVID-19 patients by measuring the levels of ferritin heavy chain, catalase, total superoxide dismutase (SOD) activity, total antioxidant status, iron and lipid peroxidation (Figure 4A-F). Interestingly, elevated plasma levels of ferritin (Figure 4A), catalase (Figure 4B) superoxide dismutase (Figure 4C) and lipid peroxidation (Figure 4F) were found in COVID-19 patients compared to HC individuals whereas no significant difference was observed in the levels of total antioxidant response (Figure 4D) and iron (Figure 4E) in the same set of samples.

Mitochondrial superoxide is an important intracellular source of reactive oxygen species and plays a critical role in promoting Fenton/Haber-Weiss reactions by releasing iron from intracellular ferritin complex, which in turn

culminates in the generation of highly reactive hydroxyl radicals (Biemond et al., 1986; Biemond et al., 1984; Bou-Abdallah et al., 2018; Monteiro and Winterbourn, 1988; Williams et al., 1974). Elevated levels of hydroxy radicals in turn lead to abnormal generation and accumulation of toxic lipid peroxides affecting host cell function and viability. To carefully assess oxidative stress response in COVID-19 patients at the cellular level, we evaluated mitochondrial superoxide generation and lipid peroxidation in circulating CD14^{high}CD16⁻ monocytes from COVID-19 patients (n=40) and HCs (n=23) by flow cytometric analysis. In addition, we used PBMC lysates from COVID-19 patients and HCs to investigate the host cellular antioxidant response by assessing intracellular levels of glutathione. We found elevated levels of mitochondrial superoxide along with aberrant lipid peroxidation in CD14^{high}CD16⁻ monocytes from COVID-19 patients compared to HCs (Figure 4G and 4H, respectively). Consistent with these observations, a major reduction in intracellular glutathione levels was observed in PBMC lysates from COVID-19 patients compared to HCs (Figure 4I), suggesting an impaired intracellular host antioxidant response to control oxidative stress responses and ultimately lipid peroxidation.

Exacerbated inflammasome activation is associated with mitochondrial dysfunction in COVID-19 patients

We next sought to evaluate associations between cellular inflammatory responses and oxidative stress in monocytes from COVID-19 patients and HCs. We found strong negative correlations between lipid peroxidation, mitochondrial superoxide and inflammasome activation and the frequency of

1 CD14^{low}CD16⁺ monocytes as well as CCR2 expression on CD14^{high}CD16⁻
 2 monocytes (Figure 5A). A highly significant negative correlation between
 3 glutathione levels and lipid peroxidation along with ASC-specks was also
 4 observed (Figure 5A), suggesting a possible link between cell stress
 5 responses and inflammasome activation during COVID-19.

6 Monocyte secretion of IL-1 β and IL-18 as a result of NLRP3
 7 inflammasome activation requires mitochondrial-derived ROS and is
 8 commonly associated with an imbalance of cellular redox status (Martinon,
 9 2010; Tschopp and Schroder, 2010). To assess the level of mitochondrial
 10 perturbation on monocytes isolated from COVID-19 patients, we incubated
 11 total PBMC with MitoTracker probe in order to evaluate mitochondrial
 12 membrane potential ($\Delta\Psi_m$) in CD14^{high}CD16⁻ monocytes by imaging flow
 13 cytometry. This approach was also employed to address whether
 14 mitochondrial perturbation or dysfunction is associated with inflammasome
 15 assembly measured here by ASC-speck formation. CD14^{high}CD16⁻ monocytes
 16 from COVID-19 patients were grouped according to their ASC-speck status in
 17 CD14^{high}ASC-speck^{neg} (resting cells) and CD14^{high}ASC-speck^{pos} cells and the
 18 loss of mitochondrial membrane potential was determined a decrease in
 19 MitoTracker MFI (Figure 5B). ASC-speck^{pos} monocytes showed an elevated
 20 frequency of cells displaying small puncta of MitoTracker staining compared
 21 to ASC-speck^{neg} cells (Figure 5C). In contrast, decreased MitoTracker gMFI
 22 was found in cells displaying ASC speck formation (Figure 5D), demonstrating
 23 loss of mitochondrial membrane potential and inflammasome activation in
 24 CD14^{high}CD16⁻ monocytes.

1 Mitochondrial dysfunction is also linked with a metabolic shift from
2 OXPHOS to glycolysis in inflammatory immune cells (Angajala et al., 2018;
3 Monteiro et al., 2020). To investigate whether monocytes obtained from
4 COVID-19 patients display this metabolic shift, we stained cells for Glut-1.
5 Supporting our MitoTracker results, we found that CD14^{high}CD16⁻ monocytes
6 from COVID-19 patients showed elevated levels of Glut-1 (Supplemental
7 Figure 3A), suggesting that these cells are undergoing intense cellular stress,
8 reflecting by altered cell metabolism. Further, we found no difference in Glut-1
9 level when patients were grouped based on their disease severity status
10 (Supplemental Figure 3B).

11 Aberrant oxidative stress response strongly correlates with robust **12 caspase-1 activation in COVID-19 patients**

13 We have shown that COVID-19 patients display elevated caspase-1
14 activity and accumulation of lipid peroxides in circulating CD14^{high}CD16⁻
15 monocytes. As the oxidative stress response expressed by lipid peroxidation
16 also modulates NLRP3-inflammasome activation and the consequent release
17 of mature IL-1 β and IL-18 (Martinon, 2010; Tschopp and Schroder, 2010), we
18 extended our analyses to explore the correlation between inflammasome
19 activation and the oxidative stress response and their impact on disease
20 severity.

21 We first investigated whether levels of mitochondrial superoxide in
22 COVID-19 patients correlate with capase-1 activity. As shown in Figure 5E we
23 observed a significant positive correlation between mitoSOX (gMFI) and
24 FLICA (gMFI) in CD14^{high}CD16⁻ monocytes from COVID-19 patients. In

1 addition, we found a robust positive correlation between lipid peroxidation and
2 active caspase-1 (Figure 5F). To test whether these parameters can reflect
3 clinical disease severity, we stratified patients into mild or moderate-severe
4 groups. We found a significant positive correlation of mitochondrial superoxide
5 production and caspase-1 activity in monocytes from patients displaying mild
6 and moderate/severe disease (Figure 5G). However, a stronger and more
7 robust correlation was observed between lipid peroxidation and caspase-1
8 activity in patients in the moderate-severe group than those in the mild group
9 (Figure 5H). Collectively, these findings reveal that CD14^{high}CD16⁻ monocytes
10 from COVID-19 patients display dysregulated oxidative stress responses and
11 prominent inflammasome activation. Crosstalk between these two pathways
12 may negatively impact the clinical course of SARS-CoV-2-infected subjects.

13 **IL-1 β secretion by human monocytes in response to SARS-CoV-2 in** 14 **vitro requires NLRP3 inflammasome activation and is partially** 15 **dependent on lipid peroxidation**

16 We next sought to investigate the crosstalk between the oxidative
17 stress pathway and NLRP3-caspase-1 activation on circulating blood
18 monocytes during COVID-19. To do so, we incubated column-purified
19 monocytes isolated from healthy donors with SARS-CoV-2 USA-WA1/2020 at
20 different multiplicities of infection (MOI) and measured IL-1 β in supernatants
21 after 24 hours as a result of inflammasome activation. As a negative control
22 for active virus infection, monocytes were stimulated with heat-inactivated
23 virus (HI-CoV-2) or viral media alone (Mock). First, to evaluate the presence
24 of replicating virus in SARS-CoV-2-exposed monocyte cultures, we incubated

1 VERO E6 cells, a cell lineage known to be sensitive to SARS-CoV-2 infection,
2 with SARS-CoV-2-exposed monocyte lysates serially diluted. Although we
3 failed to detect robust SARS-CoV-2 replication within human monocytes by
4 using this method (Supplemental Figure 5), SARS-CoV-2 exposure to
5 monocytes was sufficient to induce IL-1 β secretion at MOI of 1, which was not
6 seen in cultures incubated with HI-CoV-2 at the same MOI or with media only
7 (mock) (Figure 6A).

8 We then examined the direct role of NLRP3 and ROS generation on
9 inflammasome activation in response to SARS-CoV-2 in our *in vitro* system,
10 by incubating monocytes with NLRP3 inhibitor MCC950 or Ferrostatin-1 (Fer-
11 1), a compound known to inhibit lipid peroxidation. Interestingly, we observed
12 that live SARS-CoV-2-induced IL-1 β production was completely abrogated by
13 MCC950 and partially inhibited by lipid peroxidation (Figure 6B). These *in vitro*
14 results suggest that lipid peroxidation, a surrogate of oxidative stress, can
15 further exacerbate NLRP3-inflammasome activation in response to SARS-
16 CoV-2.

17 **Excessive oxidative stress response and inflammatory profile persist in** 18 **COVID-19 patients after short-term recovery**

19 It has been reported that some COVID-19 patients display lingering
20 symptoms after disease recovery. This clinical condition known as post-acute
21 COVID-19 syndrome is not yet well understood and has been described even
22 in patients who experienced mild disease (Nalbandian et al., 2021; Yong,
23 2021). Since cell stress and inflammatory measures were elevated in COVID-
24 19 patients, we sought to investigate whether this exacerbated inflammatory

1 status persisted after a short recovery (approximately 52 days after infection
2 onset). To do so, we first evaluated the frequency of monocytes along with
3 expression of phenotypic or inflammatory markers such as CCR2, HLA-DR,
4 ASC-speck formation, caspase-1 activity, mitochondrial superoxide
5 generation, lipid peroxidation as well as cytokine production including IL-18,
6 IL-1 β , IL-6 and TNF- α (Figure 7A-L), by comparing those markers across
7 recovered individuals and HCs. Among all parameters tested, we observed
8 that CCR2 expression (Figure 7B), FLICA⁺ASC-speck monocyte frequency
9 (Figure 7D), caspase-1 activity (Figure 7E), lipid peroxidation (Figure 7F),
10 intracellular GSH levels (Figure 7H) and spontaneous cytokine release *in vitro*
11 were all significantly altered in the COVID-19 recovered group *versus* HCs,
12 indicating that short-term recovery does not afford a return to previous levels
13 for these measurements (Figure 7). In contrast, longitudinal analysis of
14 revealed a significant increase in CD14^{low}CD16⁺ monocytes after recovery,
15 suggesting a restoration of the normal distribution of monocytes subsets in
16 peripheral blood (Figure 7A). Additionally, measurements associated with
17 metabolic shift (Supplemental Figure 3C), cell activation (Supplemental Figure
18 4C-D), inflammasome activation (Supplemental Figure 4E-F), oxidative stress
19 (Supplemental Figure 4G-H), as well as pro-inflammatory cytokine production
20 (Supplemental Figure 4I-L) showed no significant difference between the
21 acute and recovery phase. Importantly, the sustained cellular stress and
22 inflammatory status found in the COVID-19 patients post-recovery was not
23 associated with initial disease severity, since this inflammatory profile was
24 observed regardless of patient classification at the acute phase of the disease
25 as inpatients (closed symbols) or outpatients (open symbols) (Figure 7 and

- 1 Supplemental Figure 4). These findings suggest that COVID-19-related stress
- 2 and inflammatory responses persist after short-term recovery even in patients
- 3 displaying mild symptoms at the acute phase of disease.

4

1 DISCUSSION

2 In SARS-CoV-2 infection, inflammatory monocyte-derived
3 macrophages are the prominent immune cells in the infected lungs, playing a
4 pivotal role as a major source of inflammatory mediators and thus significantly
5 contributing to disease progression (Franks et al., 2003; Nicholls et al., 2003).
6 Herein, we expand this knowledge by showing that approximately 10% of
7 circulating CD14^{high}CD16⁻ inflammatory monocytes from COVID-19 patients
8 demonstrate ASC/Caspase-1/4/5 inflammasome complex formation, which
9 appears to persist after short-term recovery. These aggregates are required
10 for caspase-1-mediated IL-1 and IL-18 secretion, highlighting the role of
11 CD14^{high}CD16⁻ monocytes in COVID-19 pathogenesis. The enhanced
12 caspase-1 activity of the pro-inflammatory monocytes strongly correlated with
13 dysregulated oxidative stress status evidenced by mitochondrial dysfunction,
14 mitochondrial superoxide generation and lipid peroxidation. Such clinical
15 findings were confirmed *in vitro*, with oxidative stress identified to be partially
16 involved in NLRP3-mediated IL-1 β secretion by monocyte cultures exposed to
17 SARS-CoV-2. Importantly, elevated inflammasome activation and aberrant
18 oxidative stress response were both strongly correlated with worse clinical
19 disease outcome, supporting the concept that myeloid-derived inflammatory
20 responses are closely associated with disease severity in COVID-19.

21 Marked phenotypic differences were observed in the monocytic
22 compartment in COVID-19 patients, including a striking depletion of the
23 CD14^{low}CD16⁺ patrolling monocyte subset, an expansion of the
24 CD14^{high}CD16⁻ classical/inflammatory monocytes and downmodulation of

1 HLA-DR and CCR2 markers in the CD14^{high}CD16⁺ cells as reported in other
2 studies. Robust HLA-DR downregulation in monocytes from COVID-19
3 hospitalized patients compared to HCs has been previously shown by single-
4 cell RNA sequencing analysis (Wilk et al., 2020). Dimensionality reduction
5 analysis of monocytes also indicated a strong phenotypic shift towards the
6 CD14⁺ monocyte subset in patients with acute respiratory distress syndrome
7 (Wilk et al., 2020). More recently, the SARS-CoV-2 protein ORF7a has been
8 shown to interact with CD14⁺ monocytes, triggering downmodulation of HLA-
9 DR and production of proinflammatory cytokines *in vitro* (Zhou et al., 2021). It
10 is not clear, however, whether specific viral factors may also contribute to the
11 downregulation of CCR2 on classical monocytes. CCR2 expression on
12 classical CD14^{high}CD16⁺ monocytes is known to mediate bone marrow egress
13 and recruitment into inflamed tissues in response to CCL2 (Phillips et al.,
14 2005). Several studies have shown elevated levels of CCL2 along with other
15 chemokines in serum and bronchoalveolar fluid (BALF) samples obtained
16 from COVID-19 patients, which may contribute to classical monocyte
17 expansion, substantial mononuclear cell infiltration into the lungs, and
18 consequently tissue damage (Khalil et al., 2021; Merad and Martin, 2020; Wilk
19 et al., 2020). Thus, our data suggest downmodulation of CCR2 as a possible
20 compensatory mechanism of CD14^{high} monocytes in response to sustained
21 overproduction of CCL2 or continuous trafficking of CCR2⁺ cell into tissues
22 (Aragay et al., 1998). Intriguingly, our finding showing a failure of CCR2
23 expression to return to normal levels after short-term recovery indicates
24 persistent chemokine overexpression and monocyte recruitment even after
25 the acute phase of the infection.

1 Our results also indicate NLRP3 as the main inflammasome sensor
2 promoting the poor outcome of COVID-19, in agreement with recently
3 reported studies (Marchetti et al., 2021; Rodrigues et al., 2021). In this regard,
4 the presence of NLRP3 inflammasome aggregates has been previously
5 described in PBMCs and autopsy tissue samples from COVID-19 patients
6 (Rodrigues et al., 2021; Toldo et al., 2021). Our findings extend these
7 observations by revealing that aberrant oxidative stress responses evidenced
8 by mitochondrial superoxide production and lipid peroxidation strongly
9 associate with caspase-1 activity, suggesting a crosstalk between oxidative
10 stress and inflammasome activation in SARS-CoV-2 infection. In fact,
11 intracellular ROS production has been suggested as a key trigger of NLRP3
12 inflammasome activation as a result of either direct pathogen sensing or in
13 response to DAMPs released from dying cells (Martinon, 2010; Tschopp and
14 Schroder, 2010). Previous studies have reported that SARS-CoV
15 transmembrane pore-forming protein, known as viroporin SARS-CoV 3a or
16 ORF3a, activates the NLRP3 inflammasome complex in LPS-primed
17 macrophages through a mechanism dependent on K⁺ efflux and
18 mitochondrial ROS (Chen et al., 2019). In addition, ORF3a was also shown to
19 promote inflammasome assembly through TRAF3-mediated ubiquitination of
20 ASC, while another viral protein, ORF8b seems to interact directly with the
21 leucine-rich repeat domain of NLRP3 to stimulate its activation independent of
22 ion channel activity (Shi et al., 2019). More recently, an *in vitro* study showed
23 that SARS-CoV-2 viroporin protein induces the NLRP3-inflammasome
24 formation in a lung epithelial cell line (Xu et al., 2020), suggesting that SARS-

1 CoV-2 may trigger ROS-mediated NLRP3-inflammasome activation similarly
2 to SARS-Cov.

3 It remains controversial whether circulating blood monocytes can
4 express the receptor ACE-2, the dominant entry receptor for SARS-CoV-2,
5 and thus be actively infected (Gheblawi et al., 2020; Zamorano Cuervo and
6 Grandvaux, 2020). Although initial work failed to identify ACE-2 on most
7 tissue-resident macrophages and monocytes (Merad and Martin, 2020), other
8 studies have shown ACE-2 protein expression in human circulating
9 monocytes and macrophages by immunoblotting or flow cytometry
10 (Rutkowska-Zapala et al., 2015; Zhang et al., 2021). More recent reports
11 suggest that SARS-CoV-2 can actively infect primary human monocytes,
12 resulting in NLRP3 activation and consequently IL-1 β secretion (Ferreira et
13 al., 2021; Junqueira et al., 2021; Rodrigues et al., 2021). In the present study
14 we were unable to observe productive infection in human monocytes exposed
15 to the SARS-CoV-2 virus *in vitro* (Supplemental Figure 5). A possible
16 explanation for the discrepancy between our results and others relates to the
17 different approaches used to evaluate SARS-CoV-2-monocyte infection. In
18 this regard, here we evaluated productive SARS-CoV-2 infection by exposing
19 VERO E6 indicator cells which are known to be virus susceptible, to monocyte
20 lysates, whereas other studies have employed rt-PCR or fluorescent-protein
21 reporter virus to evaluate SARS-CoV-2 infection in human monocyte cultures.

22 Nevertheless, in agreement with a role for direct monocyte sensing of
23 SARS-CoV-2 in NLRP3 activation, we observed that exposure of primary
24 human HC monocytes to the active virus was sufficient to promote NLRP3-
25 driven IL-1 β production. Importantly, SARS-CoV-2-induced IL-1 β secretion

1 was partially suppressed by treating cells with a lipid peroxidation inhibitor,
 2 Fer-1. This observation is consistent with a recent report showing that
 3 monocyte-derived macrophages and dendritic cells can be activated by
 4 SARS-CoV-2 to induce both cytokine production and cell death even in the
 5 absence of productive infection (Zheng et al., 2021). Our findings, however,
 6 do not rule out the possibility that monocytes/macrophages are able to be
 7 productively infected in patients. In addition to ACE2 binding, other potential
 8 routes of SARS-CoV-2 entry in monocytes have also been proposed such as
 9 binding of the spike protein to the CD147 receptor, antibody-mediated
 10 phagocytosis via Fc gamma receptors, as well as engulfment of dying infected
 11 cells, (Bournazos et al., 2020; Junqueira et al., 2021; Wang et al., 2020).
 12 Nonetheless, further studies with SARS-CoV-2 variants displaying different
 13 mutations are also needed to investigate whether changes in the viral genome
 14 may affect viral uptake by monocytes/macrophages.

15 A major observation of the present study is that the inflammatory
 16 profile of circulating monocytes persists in COVID-19 patients, post-recovery
 17 regardless of their disease severity during acute infection (Figure 7 and
 18 Supplemental Figure 4). It has been reported that about 80% of hospitalized
 19 patients with COVID-19 displayed at least one long-term symptom for several
 20 months after discharge, particularly fatigue and dyspnea (Arnold et al., 2020;
 21 Carfi et al., 2020). Moreover, lingering symptoms and functional impairment
 22 up to eight months after contracting mild SARS-CoV-2 infection was also
 23 reported in a group of low-risk healthcare workers (Havervall et al., 2021).
 24 Indeed, some patients in our cohort, who had experienced either mild or
 25 severe symptoms during acute COVID-19, have also reported the persistence

1 of at least one of the current known COVID-19 symptoms following recovery
 2 from infection. However, we were unable to establish a close association
 3 between the biomarkers tested in this study and any of the residual symptoms
 4 post-recovery. The pathophysiology, risk factors and treatment of post-acute
 5 COVID-19 is currently poorly understood. In that sense, our observations of
 6 sustained dysregulated oxidative stress and inflammasome activation in
 7 monocytes after short-term recovery support the current hypothesis that long
 8 term COVID-19 is driven by persistent pathological inflammation and suggest
 9 the pathways involved as potential targets for therapeutic intervention
 10 (Nalbandian et al., 2021; Yong, 2021). In this regard, it will be important to
 11 evaluate whether persistent immune activation after COVID-19 recovery relies
 12 on the presence of undetectable SARS-CoV-2 virus, viral RNA and/or viral
 13 antigens as well as assess the contribution of unrepairable cellular and tissue
 14 damage.

15 The limitations of the current study include lack of critically ill ventilated
 16 ICU patients (as participants had to be able to provide consent), lack of
 17 multiple longitudinal sampling and small sample size. Nevertheless, our
 18 findings collectively corroborate the hypothesis that early exposure of alveolar
 19 macrophages and endothelial cells to SARS-CoV-2 may induce oxidative
 20 stress dysregulation and aberrant cytokine secretion. This initial cell priming
 21 event may contribute to the enhanced recruitment to the site of infection of
 22 pre-activated circulating monocytes pre-committed to inflammasome
 23 activation and aberrant oxidative stress response, resulting in exacerbation of
 24 tissue immunopathology and ultimately organ failure. In this context, recent
 25 advances in targeting ROS by administration of glutathione or glutathione

1 precursors (N-acetyl-cysteine, NAC), as well as IL-1 signaling by
2 administering Anakinra, a IL-1 Receptor antagonist (IL-1Ra), have been
3 reported to prevent inflammation and/or worse clinical outcome in COVID-19
4 patients (Cauchois et al., 2020; Cavalli et al., 2020; Horowitz et al., 2020;
5 Huet et al., 2020; Ibrahim et al., 2020; Kyriazopoulou et al., 2021a;
6 Kyriazopoulou et al., 2021b). Thus, our findings suggest that early treatment
7 with antioxidants and IL-1 signaling inhibitors may represent potential
8 therapeutic intervention for COVID-19 by preventing deleterious effects
9 downstream of the inflammasome pathway and consequently tissue
10 immunopathology and that such interventions may have a role in the recovery
11 phase of the disease.

1 **Materials and methods**

2 **Plasma biomarker measurements**

3 Cryopreserved plasma samples from HCs and patients were assessed to
 4 measure levels of the following inflammatory biomarkers according to the
 5 manufacturer's instructions. Levels of IFN- γ , IL-2, IL-6, IL-7, IL-8, IL-10, IL-
 6 12p70, TNF- α , IL-27, E-Selectin, P-Selectin, ICAM-3, SAA, CRP, VCAM-1,
 7 ICAM-1 and IL-18 were quantified using electrochemiluminescence kits from
 8 Meso SCALE (Gaithersburg, MD, USA). Levels of ferritin heavy chain (ferritin-
 9 H) were determined by enzyme-linked immunosorbent assay (ELISA) from
 10 Thermo Fisher Scientific (Rockford, IL, USA). D-dimer levels were measured
 11 using Enzyme Linked Fluorescence Antibody kits from BioMerieux, MA, USA.
 12 Levels of iron was assessed using a commercial kit from Novus Biologicals
 13 (Centennial, CO). Concentrations of catalase, superoxide dismutase activity
 14 (SOD) and total oxidant status were measured using kits from Sigma-Aldrich
 15 (St. Louis, MO, USA). Levels of sCD14 and sIL-6Ra were quantified by ELISA
 16 from R&D Systems (Minneapolis, MN, USA). Lipid peroxidation in plasma was
 17 assessed using an assay kit from Cayman Chemical, which measures the
 18 formation of malondialdehyde (MDA).

19 **Cell culture and treatments**

20 Cryopreserved ficoll-isolated peripheral blood mononuclear cells (PBMCs)
 21 from patients or healthy control individuals (HCs) were thawed and
 22 resuspended in RPMI-1640 media (Corning, NY, USA) supplemented with
 23 10% heat-inactivated human AB serum (Gemini Bio-Products, West

1 Sacramento, USA) and 0.05% benzonase (MilliporeSigma, USA). Cells were
2 rested for 1 hour at 37 °C and 5% CO₂ and subsequently plated at 10⁶
3 cells/well in round bottom 96-well plates (Corning Costar™, MilliporeSigma,
4 USA) followed by immune staining. Alternatively, cells were incubated for 3hr,
5 in the presence or absence of MCC950 (3 μM; Invivogen, CA, USA) or
6 colchicine (10 μM; Sigma-Aldrich, St Louis, MO, USA) for inflammasome
7 inhibition. IL-1β, IL-6 and TNF-α were quantified in culture supernatants by
8 using Multi-Analyte Flow Assay Kit (LEGENDplex) from Biolegend, following
9 the manufacturer's instructions.

10 **Inflammasome and mitochondrial status assessment by Imaging Flow** 11 **Cytometry**

12 Inflammasome complex assembly was evaluated by detection of ASC speck
13 formation by imaging flow cytometry, as previously described (Lage et al.,
14 2019). Briefly, PBMCs were incubated with the fluorochrome inhibitor of
15 caspase-1/4/5 (FAM-FLICA, Immunochemistry technologies (ICT),
16 Bloomington, MN) following the manufacturer's instructions, for 50 min at
17 37 °C, to allow for binding of FLICA to activated inflammatory caspases. Cells
18 were washed twice with the FLICA kit wash buffer and then incubated with
19 LIVE/DEAD Fixable AQUA Dead Cells Stain (Thermo Fisher, USA) for 15 min
20 at RT, followed by extracellular staining in PBS + 1% BSA with the following
21 fluorochrome-conjugated antibodies for monocyte phenotyping: anti-CD14
22 BV605 (Clone:M5E2), anti-CD16 PE-Cy7 (Clone:3G8), and anti-CD3 PE
23 (Clone:HIT3a) from BioLegend, San Diego, CA, USA; anti-CD20 PE
24 (Clone:2H7), anti-CD19 PE (Clone:SJ25C1), anti-CD2 PE (Clone:RPA-2.10),

1 from eBioscience, San Diego, CA; anti-CD56 PE [(Clone: B159 (RUO))], anti-
2 HLA-DR BV421 [Clone: G46-6 (RUO)] and anti-CD66b (Clone:G10F5) from
3 BD Biosciences, Franklin Lakes, New Jersey. Cells were fixed and
4 permeabilized with Cytofix/Cytoperm (BD Biosciences, USA) overnight at 4°C
5 and stained for 1h at RT for intracellular ASC, with anti-ASC/TMS1 AF647
6 antibody from Novus Biologicals, Littleton, CO. In parallel, cells were stained
7 with monocyte markers and 200 nM Mitotracker Red (MitoTracker™ Red
8 CMXRos, Invitrogen) followed by ASC intracellular staining for mitochondrial
9 membrane potential evaluation. Cells were acquired using a 12-channel
10 Amnis ImageStreamX Mark II (MilliporeSigma) imaging flow cytometer and
11 the integrated software INSPIRE (MilliporeSigma) was used for data
12 collection. Images were analyzed using image-based algorithms in the
13 ImageStream Data Exploration and Analysis Software (IDEAS 6.2.64.0,
14 MilliporeSigma) as described previously (Lage et al., 2019).

15 **Flow Cytometry**

16 PBMCs were stained with the following list of fluorescently labeled antibodies
17 against cell surface markers subsequently detected by flow cytometry: anti-
18 CD14 BV605 (Clone:M5E2), anti-CD16 PE-Cy7/BV711 (Clone:3G8), and anti-
19 CD3 PE (Clone:HIT3a) from BioLegend; anti-CD20 e450 (Clone:2H7), anti-
20 CD19 e450 (Clone:SJ25C1), anti-CD2 e450 (Clone:RPA-2.10), from
21 eBioscience; anti-CD56 e450 [(Clone: B159 (RUO))], anti-HLA-DR APC-Cy7
22 [Clone: G46-6 (RUO)] and anti-CD66b e450 (Clone:G10F5) and CCR2 PerCP
23 Cy5.5 [Clone:] from BD Biosciences. Staining protocol proceeded as
24 described above for imaging flow cytometry analysis. Surface Glut-1 receptor

1 expression was detected by binding to the Glut-1 ligand fused to enhanced
2 green fluorescent protein (GFP) (Metafora Biosystems, Evry, France), as
3 previously described (Hammoud et al., 2019). In brief, 10^6 cells were
4 incubated for 20 minutes with 10 μ L of Glut-1–GFP solution prior to Live/Dead
5 staining using LIVE/DEAD Cell Viability Assay (Life Technologies, CA, USA).
6 GFP fluorescence was detected by staining cells with Alexa Fluor 647 anti-
7 GFP antibody at 1:200 (Biolegend). Data were acquired on a BD Fortessa
8 flow cytometer (BD Biosciences). All compensation and gating analyses were
9 performed using FlowJo 10.5.3 (TreeStar, Ashland, OR, USA).

10 **Lipid peroxidation assay**

11 Lipid peroxidation in total PBMC cultures was assessed by using the Click-iT
12 Lipid Peroxidation Imaging Kit (Life Technologies, SA, USA) according to the
13 manufacturer's instructions. Cells were incubated with the LAA reagent
14 (alkyne-modified linoleic acid) for detection of lipid peroxidation-derived
15 protein modifications at 37°C for 1 h, and then washed with 1 $\times$ DPBS. After
16 cell centrifugation (1,500 rpm for 5 min) to remove the LAA reagent, cells
17 were incubated with antibodies to measure lipid peroxidation only in CD14+
18 monocytes. Live/Dead staining was performed as described previously above
19 and the cells fixed by adding cytofix/cytoperm (BD bioscience, USA). After
20 completing the LAA staining, fixed cells were washed, and resuspended in 1 $\times$
21 DPBS, and then LAA fluorescence was analyzed by flow cytometry.

1 **Measurement of intracellular GSH levels**

2 Intracellular GSH levels were measured in PBMC lysates by using a
3 Glutathione Assay Kit (Cayman Chemical, USA) according to the
4 manufacturer's instructions. Total GSH levels were normalized by total protein
5 concentration determined by using a Pierce BCA protein Assay kit (Thermo
6 Fisher, IL, USA).

7 **Mitochondrial superoxide assay**

8 Mitochondrial superoxide was detected by using a flow cytometry-based
9 assay. Total PBMCs were washed with Hank's balanced salt solution with
10 calcium and magnesium (HBSS/Ca/Mg, Gibco, USA) to remove residual
11 media by centrifugation. Cell pellet was stained with MitoSOX probe (Life
12 Technologies, USA) at 37°C for 30 min following the manufacturer's protocol.
13 Cells were next washed with HBSS/Ca/Mg and incubated with antibodies to
14 analyze CD14⁺ monocytes by flow cytometry. Cells fixed with 2%
15 paraformaldehyde at room temperature for 30 min. Fluorescence intensity of
16 the probe was then measured by flow cytometric analysis.

17 ***In vitro* exposure of human monocytes to SARS-CoV-2**

18 Elutriated monocytes isolated from fresh PBMCs were co-cultured with SARS-
19 CoV-2 USA-WA1/2020 at different MOIs for 3 hours at 37°C under low serum
20 conditions (2% fetal calf serum) in a Biosafety Level 3 facility. Control cells
21 were co-cultured with heat-inactivated SARS-CoV-2 USA-WA1/2020 at a MOI
22 of 1, mock viral supernatant at a MOI of 1 or media alone. After 3 hours of
23 viral exposure, monocytes were treated with Ferrostatin-1 (Fer-1) (10μM;

1 Selleck, USA), MCC950 (10 μ M; Invivogen, CA, USA) or vehicle (DMSO;
2 Sigma-Aldrich, St. Louis, MO, USA) and thus incubated for an additional 21
3 hours at 37°C. Cell supernatants were harvested for quantification of IL-1 β by
4 ELISA following the manufacturer's directions (Sigma-Aldrich, USA).

5 To determine viral titers by TCID₅₀ assay, cells were harvested, lysed by
6 freeze/thawing and plated in triplicate onto Vero E6 cells using 10-fold serial
7 dilutions. Viral stock was used as a positive control. Plates were stained with
8 crystal violet after 96 hours to assess CPE. Viral titers were determined using
9 the Reed-Muench method.

10 **Statistical Analyses**

11 Statistical analyses were performed using non-parametric Mann-Whitney or
12 Kruskal-Wallis test in GraphPad Prism 8.0.1 software (GraphPad, USA). Data
13 are presented as median with interquartile ranges. Spearman's correlation
14 analyses were performed using R. Differences between groups or parameters
15 were considered significant when $p \leq 0.05$.

16 **Study participants and approval**

17 Study participants were enrolled in the NIH clinical protocol: COVID-19-
18 associated Lymphopenia Pathogenesis Study in Blood (CALYPSO),
19 NCT04401436, which recruited at the NIH clinical center, Washington
20 Hospital Center and Georgetown University Hospital. Healthy volunteer blood
21 samples were obtained under the protocol 99-CC-0168 and were de-identified
22 prior to distribution. Protocols in this study were reviewed and approved by
23 the National Institutes of Health (NIH) Central Intramural Institutional Review

1 Board (IRB). All participants provided written informed consent prior to any
2 study procedures in accordance with the Declaration of Helsinki. Patients
3 enrolled in this study were classified according to their highest oxygen
4 requirement up until the time of the research blood draw in (1) mild cases, in
5 which patients required 4 Liters or less, (2) moderate cases, when their
6 requirement was up to 50% oxygen concentration (FiO₂), and (3) severe
7 cases, in which patients required over 50% FiO₂ or ICU care. Only patients
8 who were able to consent themselves were eligible to participate, which
9 limited the enrollment of critically ill ventilated ICU patients. In addition, 14
10 patients were sampled longitudinally, at the acute phase of the disease and
11 after a short-term recovery period (approximately 52 days after infection
12 onset) and 2 patients were enrolled after their recovery.

13 **AUTHOR CONTRIBUTIONS**

14 SLL, EPA, AS and IS were involved in conception and design of the study and
15 experiments. SLL, EPA, KH, AR, SN and JR performed experiments and/or
16 data analysis. EL, PK, GW, RP, FG, AK, JR, MM, AL and IS recruited
17 patients, assisted in clinical care and helped with data curation and/or
18 visualization. AR, AS, IS, JPS and HDH provided resources and reagents.
19 SLL, EPA and IS were involved in drafting the manuscript. All authors have
20 reviewed and approved the final manuscript.

21 **ACKNOWLEDGMENTS**

22 This project was supported in part by the intramural research program of
23 NIAID/NIH, with federal funds from the National Cancer Institute, National

1 Institutes of Health, under Contract No. HHSN261200800001E. KH was
2 supported by a Malahan Institute Postdoctoral Fellowship. The content of this
3 publication does not necessarily reflect the views or policies of the
4 Department of Health and Human Services, nor does mention of trade names,
5 commercial products, or organizations imply endorsement by the U.S.
6 Government. The authors declare no competing financial interests. We are
7 grateful to the patients enrolled in protocols and blood bank healthy donors for
8 making this study possible. We also thank Drs Kumar and Woltmann and their
9 associated staff at WHC and Georgetown, as well as the OP8 Infectious
10 Diseases Clinic staff for their assistance in patient recruitment and evaluation.
11 We also thank David Stephany for his technical support.

12

13 REFERENCES

14

- 15 Abais, J.M., M. Xia, Y. Zhang, K.M. Boini, and P.L. Li. 2015. Redox regulation of
16 NLRP3 inflammasomes: ROS as trigger or effector? *Antioxid Redox Signal*
17 22:1111-1129.
- 18 Ackermann, M., S.E. Verleden, M. Kuehnel, A. Haverich, T. Welte, F. Laenger, A.
19 Vanstapel, C. Werlein, H. Stark, A. Tzankov, W.W. Li, V.W. Li, S.J. Mentzer,
20 and D. Jonigk. 2020. Pulmonary Vascular Endothelialitis, Thrombosis, and
21 Angiogenesis in Covid-19. *N Engl J Med* 383:120-128.
- 22 Agbuduwe, C., and S. Basu. 2020. Haematological manifestations of COVID-19:
23 From cytopenia to coagulopathy. *Eur J Haematol* 105:540-546.
- 24 Amaral, E.P., C.L. Vinhaes, D. Oliveira-de-Souza, B. Nogueira, K.M. Akrami, and
25 B.B. Andrade. 2021. The Interplay Between Systemic Inflammation,
26 Oxidative Stress, and Tissue Remodeling in Tuberculosis. *Antioxid Redox*
27 *Signal* 34:471-485.
- 28 Angajala, A., S. Lim, J.B. Phillips, J.H. Kim, C. Yates, Z. You, and M. Tan. 2018.
29 Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into
30 Immuno-Metabolism. *Front Immunol* 9:1605.
- 31 Aragay, A.M., M. Mellado, J.M. Frade, A.M. Martin, M.C. Jimenez-Sainz, A.C.
32 Martinez, and F. Mayor, Jr. 1998. Monocyte chemoattractant protein-1-

- 1 induced CCR2B receptor desensitization mediated by the G protein-
2 coupled receptor kinase 2. *Proc Natl Acad Sci U S A* 95:2985-2990.
- 3 Arnold, D.T., F.W. Hamilton, A. Milne, A.J. Morley, J. Viner, M. Attwood, A. Noel, S.
4 Gunning, J. Hatrick, S. Hamilton, K.T. Elvers, C. Hyams, A. Bibby, E. Moran,
5 H.I. Adamali, J.W. Dodd, N.A. Maskell, and S.L. Barratt. 2020. Patient
6 outcomes after hospitalisation with COVID-19 and implications for
7 follow-up: results from a prospective UK cohort. *Thorax*
- 8 Balendiran, G.K., R. Dabur, and D. Fraser. 2004. The role of glutathione in cancer.
9 *Cell Biochem Funct* 22:343-352.
- 10 Bhat, S.A., N. Singh, A. Trivedi, P. Kansal, P. Gupta, and A. Kumar. 2012. The
11 mechanism of redox sensing in Mycobacterium tuberculosis. *Free Radic*
12 *Biol Med* 53:1625-1641.
- 13 Biemond, P., A.J. Swaak, C.M. Beindorff, and J.F. Koster. 1986. Superoxide-
14 dependent and -independent mechanisms of iron mobilization from
15 ferritin by xanthine oxidase. Implications for oxygen-free-radical-induced
16 tissue destruction during ischaemia and inflammation. *Biochem J*
17 239:169-173.
- 18 Biemond, P., H.G. van Eijk, A.J. Swaak, and J.F. Koster. 1984. Iron mobilization
19 from ferritin by superoxide derived from stimulated polymorphonuclear
20 leukocytes. Possible mechanism in inflammation diseases. *J Clin Invest*
21 73:1576-1579.
- 22 Bonaventura, A., A. Vecchie, L. Dagna, K. Martinod, D.L. Dixon, B.W. Van Tassell, F.
23 Dentali, F. Montecucco, S. Massberg, M. Levi, and A. Abbate. 2021.
24 Endothelial dysfunction and immunothrombosis as key pathogenic
25 mechanisms in COVID-19. *Nat Rev Immunol* 21:319-329.
- 26 Bou-Abdallah, F., J.J. Paliakkara, G. Melman, and A. Melman. 2018. Reductive
27 Mobilization of Iron from Intact Ferritin: Mechanisms and Physiological
28 Implication. *Pharmaceuticals (Basel)* 11:
- 29 Bournazos, S., A. Gupta, and J.V. Ravetch. 2020. The role of IgG Fc receptors in
30 antibody-dependent enhancement. *Nat Rev Immunol* 20:633-643.
- 31 Broz, P., J. von Moltke, J.W. Jones, R.E. Vance, and D.M. Monack. 2010. Differential
32 requirement for Caspase-1 autoproteolysis in pathogen-induced cell
33 death and cytokine processing. *Cell Host Microbe* 8:471-483.
- 34 Burgunder, J.M., and B.H. Lauterburg. 1987. Decreased production of glutathione
35 in patients with cirrhosis. *Eur J Clin Invest* 17:408-414.
- 36 Carfi, A., R. Bernabei, F. Landi, and C.-P.-A.C.S.G. Gemelli Against. 2020. Persistent
37 Symptoms in Patients After Acute COVID-19. *JAMA* 324:603-605.
- 38 Cauchois, R., M. Koubi, D. Delarbre, C. Manet, J. Carvelli, V.B. Blasco, R. Jean, L.
39 Fouche, C. Bornet, V. Pauly, K. Mazodier, V. Pestre, P.A. Jarrot, C.A.
40 Dinarello, and G. Kaplanski. 2020. Early IL-1 receptor blockade in severe
41 inflammatory respiratory failure complicating COVID-19. *Proc Natl Acad*
42 *Sci U S A* 117:18951-18953.
- 43 Cavalca, V., F. Veglia, I. Squellerio, G. Marenzi, F. Minardi, M. De Metrio, G.
44 Cighetti, L. Boccotti, P. Ravagnani, and E. Tremoli. 2009. Glutathione,
45 vitamin E and oxidative stress in coronary artery disease: relevance of age
46 and gender. *Eur J Clin Invest* 39:267-272.
- 47 Cavalli, G., G. De Luca, C. Campochiaro, E. Della-Torre, M. Ripa, D. Canetti, C.
48 Oltolini, B. Castiglioni, C. Tassan Din, N. Boffini, A. Tomelleri, N. Farina, A.
49 Ruggeri, P. Rovere-Querini, G. Di Lucca, S. Martinenghi, R. Scotti, M.

- 1 Tresoldi, F. Ciceri, G. Landoni, A. Zangrillo, P. Scarpellini, and L. Dagna.
- 2 2020. Interleukin-1 blockade with high-dose anakinra in patients with
- 3 COVID-19, acute respiratory distress syndrome, and hyperinflammation:
- 4 a retrospective cohort study. *Lancet Rheumatol* 2:e325-e331.
- 5 Chaves, F.J., M.L. Mansego, S. Blesa, V. Gonzalez-Albert, J. Jimenez, M.C. Tormos, O.
- 6 Espinosa, V. Giner, A. Iradi, G. Saez, and J. Redon. 2007. Inadequate
- 7 cytoplasmic antioxidant enzymes response contributes to the oxidative
- 8 stress in human hypertension. *Am J Hypertens* 20:62-69.
- 9 Chen, I.Y., M. Moriyama, M.F. Chang, and T. Ichinohe. 2019. Severe Acute
- 10 Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3
- 11 Inflammasome. *Front Microbiol* 10:50.
- 12 Conti, P., G. Ronconi, A. Caraffa, C.E. Gallenga, R. Ross, I. Frydas, and S.K. Kritas.
- 13 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung
- 14 inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-
- 15 inflammatory strategies. *J Biol Regul Homeost Agents* 34:327-331.
- 16 Dandel, M. 2021. Pathophysiology of COVID-19-associated acute respiratory
- 17 distress syndrome. *Lancet Respir Med* 9:e4.
- 18 Delgado-Roche, L., and F. Mesta. 2020. Oxidative Stress as Key Player in Severe
- 19 Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. *Arch Med*
- 20 *Res* 51:384-387.
- 21 Erlich, J.R., E.E. To, S. Liong, R. Brooks, R. Vlahos, J.J. O'Leary, D.A. Brooks, and S.
- 22 Selemidis. 2020. Targeting Evolutionary Conserved Oxidative Stress and
- 23 Immunometabolic Pathways for the Treatment of Respiratory Infectious
- 24 Diseases. *Antioxid Redox Signal* 32:993-1013.
- 25 Fakhri, S., Z. Nouri, S.Z. Moradi, and M.H. Farzaei. 2020. Astaxanthin, COVID-19
- 26 and immune response: Focus on oxidative stress, apoptosis and
- 27 autophagy. *Phytother Res* 34:2790-2792.
- 28 Favier, A., C. Sappey, P. Leclerc, P. Faure, and M. Micoud. 1994. Antioxidant status
- 29 and lipid peroxidation in patients infected with HIV. *Chem Biol Interact*
- 30 91:165-180.
- 31 Ferreira, A.C., V.C. Soares, I.G. de Azevedo-Quintanilha, S. Dias, N. Fintelman-
- 32 Rodrigues, C.Q. Sacramento, M. Mattos, C.S. de Freitas, J.R. Temerozo, L.
- 33 Teixeira, E. Damaceno Hottz, E.A. Barreto, C.R.R. Pao, L. Palhinha, M.
- 34 Miranda, D.C. Bou-Habib, F.A. Bozza, P.T. Bozza, and T.M.L. Souza. 2021.
- 35 SARS-CoV-2 engages inflammasome and pyroptosis in human primary
- 36 monocytes. *Cell Death Discov* 7:43.
- 37 Fitzpatrick, A.M., D.P. Jones, and L.A. Brown. 2012. Glutathione redox control of
- 38 asthma: from molecular mechanisms to therapeutic opportunities.
- 39 *Antioxid Redox Signal* 17:375-408.
- 40 Fitzpatrick, A.M., W.G. Teague, L. Burwell, M.S. Brown, L.A. Brown, and N.N.S.A.R.
- 41 Program. 2011. Glutathione oxidation is associated with airway
- 42 macrophage functional impairment in children with severe asthma.
- 43 *Pediatr Res* 69:154-159.
- 44 Fitzpatrick, A.M., W.G. Teague, F. Holguin, M. Yeh, L.A. Brown, and P. Severe
- 45 Asthma Research. 2009. Airway glutathione homeostasis is altered in
- 46 children with severe asthma: evidence for oxidant stress. *J Allergy Clin*
- 47 *Immunol* 123:146-152 e148.
- 48 Franks, T.J., P.Y. Chong, P. Chui, J.R. Galvin, R.M. Lourens, A.H. Reid, E. Selbs, C.P.
- 49 McEvoy, C.D. Hayden, J. Fukuoka, J.K. Taubenberger, and W.D. Travis.

- 1 2003. Lung pathology of severe acute respiratory syndrome (SARS): a
- 2 study of 8 autopsy cases from Singapore. *Hum Pathol* 34:743-748.
- 3 Freeborn, R.A., and C.E. Rockwell. 2021. The role of Nrf2 in autoimmunity and
- 4 infectious disease: Therapeutic possibilities. *Adv Pharmacol* 91:61-110.
- 5 Freeman, T.L., and T.H. Swartz. 2020. Targeting the NLRP3 Inflammasome in
- 6 Severe COVID-19. *Front Immunol* 11:1518.
- 7 Gheblawi, M., K. Wang, A. Viveiros, Q. Nguyen, J.C. Zhong, A.J. Turner, M.K.
- 8 Raizada, M.B. Grant, and G.Y. Oudit. 2020. Angiotensin-Converting
- 9 Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin
- 10 System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ*
- 11 *Res* 126:1456-1474.
- 12 Gibson, P.G., L. Qin, and S.H. Puah. 2020. COVID-19 acute respiratory distress
- 13 syndrome (ARDS): clinical features and differences from typical pre-
- 14 COVID-19 ARDS. *Med J Aust* 213:54-56 e51.
- 15 Goutzourelas, N., M. Orfanou, I. Charizanis, G. Leon, D.A. Spandidos, and D.
- 16 Kouretas. 2018. GSH levels affect weight loss in individuals with
- 17 metabolic syndrome and obesity following dietary therapy. *Exp Ther Med*
- 18 16:635-642.
- 19 Hammoud, D.A., A. Boulougoura, G.Z. Papadakis, J. Wang, L.E. Dodd, A. Rupert, J.
- 20 Higgins, G. Roby, D. Metzger, E. Laidlaw, J.M. Mican, A. Pau, S. Lage, C.S.
- 21 Wong, A. Lisco, M. Manion, V. Sheikh, C. Millo, and I. Sereti. 2019.
- 22 Increased Metabolic Activity on 18F-Fluorodeoxyglucose Positron
- 23 Emission Tomography-Computed Tomography in Human
- 24 Immunodeficiency Virus-Associated Immune Reconstitution
- 25 Inflammatory Syndrome. *Clin Infect Dis* 68:229-238.
- 26 Havervall, S., A. Rosell, M. Phillipson, S.M. Mangsbo, P. Nilsson, S. Hober, and C.
- 27 Thalin. 2021. Symptoms and Functional Impairment Assessed 8 Months
- 28 After Mild COVID-19 Among Health Care Workers. *JAMA* 325:2015-2016.
- 29 Hojyo, S., M. Uchida, K. Tanaka, R. Hasebe, Y. Tanaka, M. Murakami, and T. Hirano.
- 30 2020. How COVID-19 induces cytokine storm with high mortality.
- 31 *Inflamm Regen* 40:37.
- 32 Horby, P.W., M. Campbell, E. Spata, J.R. Emberson, N. Staplin, G. Pessoa-Amorim,
- 33 L. Peto, M. Wiselka, L. Wiffen, S. Tiberi, B. Caplin, C. Wroe, C. Green, P.
- 34 Hine, B. Prudon, T. George, A. Wight, J.K. Baillie, B. Basnyat, M.H. Buch, L.C.
- 35 Chappell, J.N. Day, S.N. Faust, R.L. Hamers, T. Jaki, E. Juszczak, K. Jeffery,
- 36 W.S. Lim, A. Montgomery, A. Mumford, K. Rowan, G. Thwaites, M. Mafham,
- 37 R. Haynes, and M.J. Landray. 2021. Colchicine in patients admitted to
- 38 hospital with COVID-19 (RECOVERY): a randomised, controlled, open-
- 39 label, platform trial. *medRxiv* 2021.2005.2018.21257267.
- 40 Hornung, V., F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, K.A.
- 41 Fitzgerald, and E. Latz. 2008. Silica crystals and aluminum salts activate
- 42 the NALP3 inflammasome through phagosomal destabilization. *Nat*
- 43 *Immunol* 9:847-856.
- 44 Horowitz, R.I., P.R. Freeman, and J. Bruzzese. 2020. Efficacy of glutathione
- 45 therapy in relieving dyspnea associated with COVID-19 pneumonia: A
- 46 report of 2 cases. *Respir Med Case Rep* 30:101063.
- 47 Huet, T., H. Beaussier, O. Voisin, S. Jouveshomme, G. Dauriat, I. Lazareth, E. Sacco,
- 48 J.M. Naccache, Y. Bezie, S. Laplanche, A. Le Berre, J. Le Pavec, S. Salmeron,

- 1 J. Emmerich, J.J. Mourad, G. Chatellier, and G. Hayem. 2020. Anakinra for
2 severe forms of COVID-19: a cohort study. *Lancet Rheumatol* 2:e393-e400.
- 3 Ibrahim, H., A. Perl, D. Smith, T. Lewis, Z. Kon, R. Goldenberg, K. Yarta, C.
4 Staniloae, and M. Williams. 2020. Therapeutic blockade of inflammation
5 in severe COVID-19 infection with intravenous N-acetylcysteine. *Clin*
6 *Immunol* 219:108544.
- 7 Iyer, S.S., Q. He, J.R. Janczy, E.I. Elliott, Z. Zhong, A.K. Olivier, J.J. Sadler, V.
8 Knepper-Adrian, R. Han, L. Qiao, S.C. Eisenbarth, W.M. Nauseef, S.L. Cassel,
9 and F.S. Sutterwala. 2013. Mitochondrial cardiolipin is required for Nlrp3
10 inflammasome activation. *Immunity* 39:311-323.
- 11 Junqueira, C., A. Crespo, S. Ranjbar, J. Ingber, B. Parry, S. Ravid, L.B. de Lacerda, M.
12 Lewandrowski, S. Clark, F. Ho, S.M. Vora, V. Leger, C. Beakes, J. Margolin,
13 N. Russell, L. Gehrke, U.D. Adhikari, L. Henderson, E. Janssen, D. Kwon, C.
14 Sander, J. Abraham, M. Filbin, M.B. Goldberg, H. Wu, G. Mehta, S. Bell, A.E.
15 Goldfeld, and J. Lieberman. 2021. SARS-CoV-2 infects blood monocytes to
16 activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine
17 release. *medRxiv*
- 18 Khalil, B.A., N.M. Elemam, and A.A. Maghazachi. 2021. Chemokines and
19 chemokine receptors during COVID-19 infection. *Comput Struct*
20 *Biotechnol J* 19:976-988.
- 21 Kyriazopoulou, E., P. Panagopoulos, S. Metallidis, G.N. Dalekos, G. Poulakou, N.
22 Gatselis, E. Karakike, M. Saridaki, G. Loli, A. Stefos, D. Prasianaki, S.
23 Georgiadou, O. Tsachouridou, V. Petrakis, K. Tsiakos, M. Kosmidou, V.
24 Lygoura, M. Dareioti, H. Millionis, I.C. Papanikolaou, K. Akinosoglou, D.M.
25 Myrodia, A. Gravvani, A. Stamou, T. Gkavogianni, K. Katrini, T. Marantos,
26 I.P. Trontzas, K. Syrigos, L. Chatzis, S. Chatzis, N. Vechlidis, C. Avgoustou, S.
27 Chalvatzis, M. Kyprianou, J.W. van der Meer, J. Eugen-Olsen, M.G. Netea,
28 and E.J. Giamarellos-Bourboulis. 2021a. An open label trial of anakinra to
29 prevent respiratory failure in COVID-19. *Elife* 10:
- 30 Kyriazopoulou, E., G. Poulakou, H. Millionis, S. Metallidis, G. Adamis, K. Tsiakos, A.
31 Fragkou, A. Rapti, C. Damoulari, M. Fantoni, I. Kalomenidis, G. Chrysos, A.
32 Angheben, I. Kainis, Z. Alexiou, F. Castelli, F.S. Serino, M. Tsilika, P.
33 Bakakos, E. Nicastri, V. Tzavara, E. Kostis, L. Dagna, P. Koufargyris, K.
34 Dimakou, S. Savvanis, G. Tzatzagou, M. Chini, G. Cavalli, M. Bassetti, K.
35 Katrini, V. Kotsis, G. Tsoukalas, C. Selmi, I. Bliziotis, M. Samarkos, M.
36 Doumas, S. Ktena, A. Masgala, I. Papanikolaou, M. Kosmidou, D.M.
37 Myrodia, A. Argyraki, C.S. Cardellino, K. Koliakou, E.I. Katsigianni, V. Rapti,
38 E. Giannitsioti, A. Cingolani, S. Micha, K. Akinosoglou, O. Liatsis-Douvitsas,
39 S. Symbardi, N. Gatselis, M. Mouktaroudi, G. Ippolito, E. Florou, A. Kotsaki,
40 M.G. Netea, J. Eugen-Olsen, M. Kyprianou, P. Panagopoulos, G.N. Dalekos,
41 and E.J. Giamarellos-Bourboulis. 2021b. Early treatment of COVID-19 with
42 anakinra guided by soluble urokinase plasminogen receptor plasma
43 levels: a double-blind, randomized controlled phase 3 trial. *Nat Med*
- 44 Lage, S.L., V.M. Dominical, C.S. Wong, and I. Sereti. 2019. Evaluation of Canonical
45 Inflammasome Activation in Human Monocytes by Imaging Flow
46 Cytometry. *Front Immunol* 10:1284.
- 47 Lopes, M.I., L.P. Bonjorno, M.C. Giannini, N.B. Amaral, P.I. Menezes, S.M. Dib, S.L.
48 Gigante, M.N. Benatti, U.C. Rezek, L.L. Emrich-Filho, B.A.A. Sousa, S.C.L.
49 Almeida, R. Luppino Assad, F.P. Veras, A. Schneider, T.S. Rodrigues, L.O.S.

- 1 Leiria, L.D. Cunha, J.C. Alves-Filho, T.M. Cunha, E. Arruda, C.H. Miranda, A.
- 2 Pazin-Filho, M. Auxiliadora-Martins, M.C. Borges, B.A.L. Fonseca, V.R.
- 3 Bollela, C.M. Del-Ben, F.Q. Cunha, D.S. Zamboni, R.C. Santana, F.C. Vilar, P.
- 4 Louzada-Junior, and R.D.R. Oliveira. 2021. Beneficial effects of colchicine
- 5 for moderate to severe COVID-19: a randomised, double-blinded, placebo-
- 6 controlled clinical trial. *RMD Open* 7:
- 7 Lu, A., V.G. Magupalli, J. Ruan, Q. Yin, M.K. Atianand, M.R. Vos, G.F. Schroder, K.A.
- 8 Fitzgerald, H. Wu, and E.H. Egelman. 2014. Unified polymerization
- 9 mechanism for the assembly of ASC-dependent inflammasomes. *Cell*
- 10 156:1193-1206.
- 11 Lutchmansingh, F.K., J.W. Hsu, F.I. Bennett, A.V. Badaloo, N. McFarlane-Anderson,
- 12 G.M. Gordon-Strachan, R.A. Wright-Pascoe, F. Jahoor, and M.S. Boyne.
- 13 2018. Glutathione metabolism in type 2 diabetes and its relationship with
- 14 microvascular complications and glycemia. *PLoS One* 13:e0198626.
- 15 Marchetti, C., K. Mould, I.W. Tengesdal, W.J. Janssen, and C.A. Dinarello. 2021.
- 16 Targeting of the NLRP3 Inflammasome for early COVID-19. *bioRxiv*
- 17 2021.2002.2024.432734.
- 18 Martinon, F. 2010. Signaling by ROS drives inflammasome activation. *Eur J*
- 19 *Immunol* 40:616-619.
- 20 Martinon, F., K. Burns, and J. Tschopp. 2002. The inflammasome: a molecular
- 21 platform triggering activation of inflammatory caspases and processing of
- 22 proIL-beta. *Mol Cell* 10:417-426.
- 23 Meduri, G.U., S. Headley, G. Kohler, F. Stentz, E. Tolley, R. Umberger, and K.
- 24 Leeper. 1995. Persistent elevation of inflammatory cytokines predicts a
- 25 poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent
- 26 and efficient predictors of outcome over time. *Chest* 107:1062-1073.
- 27 Merad, M., and J.C. Martin. 2020. Pathological inflammation in patients with
- 28 COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol*
- 29 20:355-362.
- 30 Misawa, T., M. Takahama, T. Kozaki, H. Lee, J. Zou, T. Saitoh, and S. Akira. 2013.
- 31 Microtubule-driven spatial arrangement of mitochondria promotes
- 32 activation of the NLRP3 inflammasome. *Nat Immunol* 14:454-460.
- 33 Monteiro, H.P., and C.C. Winterbourn. 1988. The superoxide-dependent transfer
- 34 of iron from ferritin to transferrin and lactoferrin. *Biochem J* 256:923-928.
- 35 Monteiro, L.B., G.G. Davanzo, C.F. de Aguiar, and P.M.M. Moraes-Vieira. 2020.
- 36 Using flow cytometry for mitochondrial assays. *MethodsX* 7:100938.
- 37 Munoz-Planillo, R., P. Kuffa, G. Martinez-Colon, B.L. Smith, T.M. Rajendiran, and G.
- 38 Nunez. 2013. K(+) efflux is the common trigger of NLRP3 inflammasome
- 39 activation by bacterial toxins and particulate matter. *Immunity* 38:1142-
- 40 1153.
- 41 Nalbandian, A., K. Sehgal, A. Gupta, M.V. Madhavan, C. McGroder, J.S. Stevens, J.R.
- 42 Cook, A.S. Nordvig, D. Shalev, T.S. Sehrawat, N. Ahluwalia, B. Bikdeli, D.
- 43 Dietz, C. Der-Nigoghossian, N. Liyanage-Don, G.F. Rosner, E.J. Bernstein, S.
- 44 Mohan, A.A. Beckley, D.S. Seres, T.K. Choueiri, N. Uriel, J.C. Ausiello, D.
- 45 Accili, D.E. Freedberg, M. Baldwin, A. Schwartz, D. Brodie, C.K. Garcia,
- 46 M.S.V. Elkind, J.M. Connors, J.P. Bilezikian, D.W. Landry, and E.Y. Wan.
- 47 2021. Post-acute COVID-19 syndrome. *Nat Med* 27:601-615.
- 48 Nicholls, J.M., L.L. Poon, K.C. Lee, W.F. Ng, S.T. Lai, C.Y. Leung, C.M. Chu, P.K. Hui,
- 49 K.L. Mak, W. Lim, K.W. Yan, K.H. Chan, N.C. Tsang, Y. Guan, K.Y. Yuen, and

- 1 J.S. Peiris. 2003. Lung pathology of fatal severe acute respiratory
2 syndrome. *Lancet* 361:1773-1778.
- 3 Ntyonga-Pono, M.P. 2020. COVID-19 infection and oxidative stress: an under-
4 explored approach for prevention and treatment? *Pan Afr Med J* 35:12.
- 5 Patton, L.M., B.S. Saggart, N.K. Ahmed, J.A. Leff, and J.E. Repine. 1995. Interleukin-
6 1 beta-induced neutrophil recruitment and acute lung injury in hamsters.
7 *Inflammation* 19:23-29.
- 8 Perricone, C., E. Bartoloni, R. Bursi, G. Cafaro, G.M. Guidelli, Y. Shoenfeld, and R.
9 Gerli. 2020. COVID-19 as part of the hyperferritinemic syndromes: the
10 role of iron depletion therapy. *Immunol Res* 68:213-224.
- 11 Phillips, R.J., M. Lutz, and B. Premack. 2005. Differential signaling mechanisms
12 regulate expression of CC chemokine receptor-2 during monocyte
13 maturation. *J Inflamm (Lond)* 2:14.
- 14 Pohanka, M. 2013. Role of oxidative stress in infectious diseases. A review. *Folia*
15 *Microbiol (Praha)* 58:503-513.
- 16 Prabhakar, N.R., Y.J. Peng, and J. Nanduri. 2020. Hypoxia-inducible factors and
17 obstructive sleep apnea. *J Clin Invest* 130:5042-5051.
- 18 Rahman, I., and W. MacNee. 1999. Lung glutathione and oxidative stress:
19 implications in cigarette smoke-induced airway disease. *Am J Physiol*
20 277:L1067-1088.
- 21 Rodrigues, T.S., K.S.G. de Sa, A.Y. Ishimoto, A. Becerra, S. Oliveira, L. Almeida, A.V.
22 Goncalves, D.B. Perucello, W.A. Andrade, R. Castro, F.P. Veras, J.E. Toller-
23 Kawahisa, D.C. Nascimento, M.H.F. de Lima, C.M.S. Silva, D.B. Caetite, R.B.
24 Martins, I.A. Castro, M.C. Pontelli, F.C. de Barros, N.B. do Amaral, M.C.
25 Giannini, L.P. Bonjorno, M.I.F. Lopes, R.C. Santana, F.C. Vilar, M.
26 Auxiliadora-Martins, R. Luppino-Assad, S.C.L. de Almeida, F.R. de Oliveira,
27 S.S. Batah, L. Siyuan, M.N. Benatti, T.M. Cunha, J.C. Alves-Filho, F.Q. Cunha,
28 L.D. Cunha, F.G. Frantz, T. Kohlsdorf, A.T. Fabro, E. Arruda, R.D.R. de
29 Oliveira, P. Louzada-Junior, and D.S. Zamboni. 2021. Inflammasomes are
30 activated in response to SARS-CoV-2 infection and are associated with
31 COVID-19 severity in patients. *J Exp Med* 218:
- 32 Rutkowska-Zapala, M., M. Suski, R. Szatanek, M. Lenart, K. Weglarczyk, R.
33 Olszanecki, T. Grodzicki, M. Strach, J. Gasowski, and M. Siedlar. 2015.
34 Human monocyte subsets exhibit divergent angiotensin I-converting
35 activity. *Clin Exp Immunol* 181:126-132.
- 36 Satis, H., H.S. Ozger, P. Aysert Yildiz, K. Hizel, O. Gulbahar, G. Erbas, G. Aygencel, O.
37 Guzel Tunccan, M.A. Ozturk, M. Dizbay, and A. Tufan. 2021. Prognostic
38 value of interleukin-18 and its association with other inflammatory
39 markers and disease severity in COVID-19. *Cytokine* 137:155302.
- 40 Sekhar, R.V., S.V. McKay, S.G. Patel, A.P. Guthikonda, V.T. Reddy, A.
41 Balasubramanyam, and F. Jahoor. 2011. Glutathione synthesis is
42 diminished in patients with uncontrolled diabetes and restored by dietary
43 supplementation with cysteine and glycine. *Diabetes Care* 34:162-167.
- 44 Shah, A. 2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A
45 Potential Drug Target in the Treatment of COVID-19. *Front Immunol*
46 11:1021.
- 47 Sharma, D., and T.D. Kanneganti. 2016. The cell biology of inflammasomes:
48 Mechanisms of inflammasome activation and regulation. *J Cell Biol*
49 213:617-629.

- 1 Shaw, S., K.P. Rubin, and C.S. Lieber. 1983. Depressed hepatic glutathione and
2 increased diene conjugates in alcoholic liver disease. Evidence of lipid
3 peroxidation. *Dig Dis Sci* 28:585-589.
- 4 Shi, C.S., N.R. Nabar, N.N. Huang, and J.H. Kehrl. 2019. SARS-Coronavirus Open
5 Reading Frame-8b triggers intracellular stress pathways and activates
6 NLRP3 inflammasomes. *Cell Death Discov* 5:101.
- 7 Shi, J., Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, and
8 F. Shao. 2015. Cleavage of GSDMD by inflammatory caspases determines
9 pyroptotic cell death. *Nature* 526:660-665.
- 10 Shimizu, H., Y. Kiyohara, I. Kato, T. Kitazono, Y. Tanizaki, M. Kubo, H. Ueno, S.
11 Ibayashi, M. Fujishima, and M. Iida. 2004. Relationship between plasma
12 glutathione levels and cardiovascular disease in a defined population: the
13 Hisayama study. *Stroke* 35:2072-2077.
- 14 Slaats, J., J. Ten Oever, F.L. van de Veerdonk, and M.G. Netea. 2016. IL-1beta/IL-
15 6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections.
16 *PLoS Pathog* 12:e1005973.
- 17 Tan, K.S., K.O. Lee, K.C. Low, A.M. Gamage, Y. Liu, G.Y. Tan, H.Q. Koh, S. Alonso, and
18 Y.H. Gan. 2012. Glutathione deficiency in type 2 diabetes impairs cytokine
19 responses and control of intracellular bacteria. *J Clin Invest* 122:2289-
20 2300.
- 21 Tang, Y., J. Liu, D. Zhang, Z. Xu, J. Ji, and C. Wen. 2020. Cytokine Storm in COVID-
22 19: The Current Evidence and Treatment Strategies. *Front Immunol*
23 11:1708.
- 24 Tardif, J.C., N. Bouabdallaoui, P.L. L'Allier, D. Gaudet, B. Shah, M.H. Pillinger, J.
25 Lopez-Sendon, P. da Luz, L. Verret, S. Audet, J. Dupuis, A. Denault, M.
26 Pelletier, P.A. Tessier, S. Samson, D. Fortin, J.D. Tardif, D. Busseuil, E.
27 Goulet, C. Lacoste, A. Dubois, A.Y. Joshi, D.D. Waters, P. Hsue, N.E. Lapor, F.
28 Lesage, N. Sainture, E. Roy-Clavel, Z. Bassevitch, A. Orfanos, G.
29 Stamatescu, J.C. Gregoire, L. Busque, C. Lavallee, P.O. Hetu, J.S. Paquette,
30 S.G. Deftereos, S. Levesque, M. Cossette, A. Nozza, M. Chabot-Blanchet,
31 M.P. Dube, M.C. Guertin, G. Boivin, and C. Investigators. 2021. Colchicine
32 for community-treated patients with COVID-19 (COLCORONA): a phase 3,
33 randomised, double-blinded, adaptive, placebo-controlled, multicentre
34 trial. *Lancet Respir Med*
- 35 Toldo, S., R. Bussani, V. Nuzzi, A. Bonaventura, A.G. Mauro, A. Cannata, R. Pillappa,
36 G. Sinagra, P. Nana-Sinkam, P. Sime, and A. Abbate. 2021. Inflammasome
37 formation in the lungs of patients with fatal COVID-19. *Inflamm Res* 70:7-
38 10.
- 39 Traverso, N., R. Ricciarelli, M. Nitti, B. Marengo, A.L. Furfaro, M.A. Pronzato, U.M.
40 Marinari, and C. Domenicotti. 2013. Role of glutathione in cancer
41 progression and chemoresistance. *Oxid Med Cell Longev* 2013:972913.
- 42 Tschopp, J., and K. Schroder. 2010. NLRP3 inflammasome activation: The
43 convergence of multiple signalling pathways on ROS production? *Nat Rev*
44 *Immunol* 10:210-215.
- 45 Wang, K., W. Chen, Z. Zhang, Y. Deng, J.Q. Lian, P. Du, D. Wei, Y. Zhang, X.X. Sun, L.
46 Gong, X. Yang, L. He, L. Zhang, Z. Yang, J.J. Geng, R. Chen, H. Zhang, B. Wang,
47 Y.M. Zhu, G. Nan, J.L. Jiang, L. Li, J. Wu, P. Lin, W. Huang, L. Xie, Z.H. Zheng,
48 K. Zhang, J.L. Miao, H.Y. Cui, M. Huang, J. Zhang, L. Fu, X.M. Yang, Z. Zhao, S.
49 Sun, H. Gu, Z. Wang, C.F. Wang, Y. Lu, Y.Y. Liu, Q.Y. Wang, H. Bian, P. Zhu,

and Z.N. Chen. 2020. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct Target Ther* 5:283.

WHO. 2021. WHO Coronavirus (COVID-19) Dashboard. In World Health Organization.

Wilk, A.J., A. Rustagi, N.Q. Zhao, J. Roque, G.J. Martinez-Colon, J.L. McKechnie, G.T. Ivison, T. Ranganath, R. Vergara, T. Hollis, L.J. Simpson, P. Grant, A. Subramanian, A.J. Rogers, and C.A. Blish. 2020. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat Med* 26:1070-1076.

Williams, D.M., G.R. Lee, and G.E. Cartwright. 1974. The role of superoxide anion radical in the reduction of ferritin iron by xanthine oxidase. *J Clin Invest* 53:665-667.

Wu, C., X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang, X. Zhou, C. Du, Y. Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu, X. Zhou, D. Chen, W. Xiong, L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng, and Y. Song. 2020. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 180:934-943.

Xu, H., S.A. Chitre, I.A. Akinyemi, J.C. Loeb, J.A. Lednický, M.T. McIntosh, and S. Bhaduri-McIntosh. 2020. SARS-CoV-2 viroporin triggers the NLRP3 inflammatory pathway. *bioRxiv* 2020.2010.2027.357731.

Yong, S.J. 2021. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. *Infect Dis (Lond)* 1-18.

Zamorano Cuervo, N., and N. Grandvaux. 2020. ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. *Elife* 9:

Zhang, D., R. Guo, L. Lei, H. Liu, Y. Wang, Y. Wang, H. Qian, T. Dai, T. Zhang, Y. Lai, J. Wang, Z. Liu, T. Chen, A. He, M. O'Dwyer, and J. Hu. 2021. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. *J Leukoc Biol* 109:13-22.

Zheng, J., Y. Wang, K. Li, D.K. Meyerholz, C. Allamargot, and S. Perlman. 2021. Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells. *J Infect Dis* 223:785-795.

Zhou, R., A.S. Yazdi, P. Menu, and J. Tschopp. 2011. A role for mitochondria in NLRP3 inflammasome activation. *Nature* 469:221-225.

Zhou, Z., C. Huang, Z. Zhou, Z. Huang, L. Su, S. Kang, X. Chen, Q. Chen, S. He, X. Rong, F. Xiao, J. Chen, and S. Chen. 2021. Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor for human CD14(+) monocytes. *iScience* 24:102187.

1 FIGURES

2

3 **Figure 1. Phenotypic changes in circulating monocyte subsets during**

4 **COVID-19.** (A) Representative FACS plots showing the distribution of the

5 monocyte subsets defined by CD14 and CD16 markers in COVID-19 patients.

6 Percentage of CD14^{low}CD16⁺ (B) and CD14^{high}CD16⁻ (C) monocytes among

7 circulating mononuclear myeloid cells

8 (HLADR⁺CD2⁻CD3⁻CD19⁻CD20⁻CD56⁻CD66⁻) were compared between

9 healthy controls (HC, n=21) and COVID-19 patients (n = 38). Data are

10 presented as median with interquartile range. The geometric mean

1 fluorescence intensity (gMFI) of HLA-DR (**D**) and CCR2 (**E**) expression on
2 CD14^{high}CD16⁻ monocytes was compared between HC (n=21) and COVID-19
3 patients (n=38). Percentage of CD14^{high}CD16⁻ (**F**) and CD14^{low}CD16⁺ (**G**)
4 monocytes as well as MFI of HLA-DR (**H**) and CCR2 (**I**) expression on
5 CD14^{high}CD16⁻ monocytes is compared between COVID-19 patients
6 experiencing mild symptoms (n=22) versus moderate to severe forms of
7 COVID-19 (n=16). Data were analyzed using the Mann-Whitney test. ***P
8 <0.001, ****P <0.0001; *ns*, not significant.

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

1
2 **Figure 2. COVID-19 patients exhibit a high frequency of monocytes**
3 **displaying FLICA⁺ASC-speck formation.** (A) Plasma levels of IL-18 were
4 compared between healthy control (HC) donors (n=9) and COVID-19 patients
5 (n=39). Lines represent median values and interquartile ranges. (B) PBMCs
6 were incubated with the fluorochrome inhibitor of caspase-1/4/5 (FLICA) and
7 the geometric mean fluorescence intensity (gMFI) of FLICA within the
8 CD14^{high}CD16⁻ monocyte subset was compared between HC (n=21) and
9 COVID-19 patients (n=38). Data are presented as median with interquartile
10 range. (C) PBMCs from HC (n=24) and COVID-19 patients (n=32) were
11 incubated with FLICA, stained for monocyte identification and intracellular
12 ASC and acquired by using Imaging flow cytometry. Representative images
13 showing respectively: CD14, CD16, ASC and FLICA fluorescence followed by
14 a composite image containing brightfield (BF), and the fluorescence of ASC
15 and FLICA merged, were selected from a COVID-19 patient. (D) The

percentage of monocytes showing spontaneous FLICA⁺ASC-Speck formation was quantified after application of Modulation_Morphology (M11,Ch11)_11-ASC feature, followed by Bright Detail Similarity R3_MC_11-ASC_2-FLICA, inside the CD14^{high}CD16⁻ monocyte gate, by using IDEAS software. Lines represent median values and interquartile ranges. (E) Spearman correlations between plasma levels of IL-18 and the percentage of ASC-speck⁺FLICA⁺ CD14^{high}CD16⁻ monocytes in COVID-19 patient samples. Percentage of ASC-speck⁺FLICA⁺ cells (F) and plasma levels of IL-18 (G) were compared between COVID-19 patients experiencing mild symptoms (n=18 and n=28, respectively) and moderate to severe cases of COVID-19 (n=13 and n=12, respectively). Lines represent median values and interquartile ranges. Data were analyzed using the Mann-Whitney test. *P <0.05, **P <0.01, ****P <0.0001.

Figure 3. Effects of the NLRP3 inhibitor MCC950 and colchicine on cytokine secretion by COVID-19 PBMCs. IL-1 β (A), IL-6 (B) and TNF α (C) levels from supernatants of healthy control (HC, n=7) or COVID-19 patients PBMCs (n=16) after a 4 hr incubation at 37C, were determined by multi-analyte flow assay kit. Lines represent median values and interquartile ranges. Alternatively, COVID-19 cells were pretreated with the NLRP3 inhibitor, MCC950 (10 μ M; n=9) or colchicine (10 μ M; n=7) during the incubation period, and IL-1 β (D), IL-6 (E) and TNF α (F) levels were measured in the culture supernatants by multi-analyte flow assay kit. Numbers represent the median values and interquartile ranges. Data were analyzed using the Mann-Whitney test. **P <0.01, ***P <0.001, ****P <0.0001; ns, not significant.

1

2 **Figure 4. Measures of oxidative stress in COVID-19 patients.** Plasma
3 levels of ferritin (A), Catalase (B), Superoxide dismutase (SOD) (C), Trolox
4 (D) Iron (E) and Lipid peroxidation (F) were compared between healthy
5 control (HC) donors (n=10-12) and COVID-19 patients (n=20-40). Lipid
6 peroxidation (LAA) (G) and mitochondrial superoxide (MitoSOX) (H) in
7 CD14^{high}CD16^{low} monocytes was measured by flow cytometry in PBMC
8 samples from HC (n=22) and COVID-19 patients (n=40). Data are expressed
9 as the geometric mean fluorescence intensity (gMFI) over average of HC. (I)

1 Intracellular glutathione (GSH) levels in PBMC lysates from HC (n=17) and
2 COVID-19 patients (n=27) were determined by analytic enzymatic assay as
3 described in Methods. Data are presented as median values and interquartile
4 ranges and analyzed using Mann-Whitney test. *P <0.05, **P <0.01, ***P
5 <0.001, ****P <0.0001; *ns*, not significant.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Figure 5. Oxidative stress and inflammasome responses are associated in COVID-19 patients. (A) Multi-parameter Spearman's correlation analysis of PBMC samples from healthy control (HC) and COVID-19 patients (*P <0.05 or less). (B) PBMCs from COVID-19 patients (n=6) were incubated with Mitotracker Red, stained for intracellular ASC and acquired by means of Imaging flow cytometry. Representative images showing respectively: BF (brightfield), Mitotracker Red, ASC and a composite image of both Mitotracker Red and ASC markers merged, were selected from a CD14⁺ASC-speck^{neg} gate (top panel) and a CD14⁺ASC-speck^{pos} gate (bottom panel). (C) The percentage of monocytes showing the diffuse pattern for Mitotracker Red shown in B (top panel) versus the aggregated staining profile as shown in B (bottom panel) was determined after application of Major Axis

1 Intensity_M04_Ch4 x Mean Pixel_M04_Ch4 features inside both CD14⁺ASC-
2 speck^{neg} and CD14⁺ASC-speck^{pos} gates using IDEAS software. **(D)** Loss of
3 mitochondrial membrane potential ($\Delta\Psi_m$) was determined by the change of
4 Mitotracker Red gMFI staining on CD14⁺ASC-speck^{neg} and CD14⁺ASC-
5 speck^{pos} subsets. Data are presented as median values and interquartile
6 ranges and were analyzed using the Mann-Whitney test (**P < 0.01). **(E-F)**
7 Spearman correlations between FLICA and MitoSOX **(E)** or FLICA and LAA
8 **(F)** levels within CD14^{high}CD16⁻ monocytes from COVID-19 patients. **(G-H)**
9 Spearman correlations between FLICA and MitoSOX **(G)** or FLICA and LAA
10 levels **(H)** on CD14^{high}CD16⁻ monocytes obtained from COVID-19 patients
11 grouped based on their disease severity in patients experiencing mild
12 symptoms (top panel, green) or moderate to severe cases of COVID-19
13 (bottom panel, red). Each dot represents a correspondent value from each
14 patient. *ns*, not significant.

15

16

Figure 6. Exposure of human healthy control monocytes to SARS-CoV-2 *in vitro* induces IL-1 β by a mechanism involving both inflammasome activation and lipid peroxidation. (A) Elutriated monocytes isolated from fresh healthy donors PBMCs were co-cultured with live SARS-CoV-2 (USA-WA1/2020) at distinct MOIs (0.1, 0.5 or 1), media only (mock) or heat inactivated SARS-CoV-2 (HI Cov-2) and IL-1 β levels were measured in the culture supernatants after 24 hours by ELISA. Data represent the means $\pm$ SEM of triplicate samples. Statistical significance was assessed by one-way ANOVA analysis for the indicated experimental conditions. *P <0.05, ****P <0.0001. (B) Healthy donor monocytes were incubated with SARS-CoV-2 at

1 MOI of 1 and treated or not with the NLRP3 inhibitor, MCC950 (10 μ M) or the
2 lipid peroxidation inhibitor, Fer-1 (10 μ M). IL-1 β levels were measured in
3 culture supernatants after 24 hours by ELISA. Data represent the means $\pm$
4 SEM of 2 independent experiments pooled with 5-6 replicates. Statistical
5 significance was assessed by one-way ANOVA analysis for the indicated
6 experimental conditions. **P < 0.01, ***P < 0.001, ****P < 0.0001.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Figure 7. Measurements associated with inflammatory responses persist in COVID-19 patients after short-term recovery. Oxidative stress and inflammatory markers were compared between HCs and COVID-19 patients after recovery (median of 52 days IQR: 47.3-75.3, after infection onset) as follows: **(A)** Percentage of patrolling CD14^{low}CD16⁺ monocyte subset, **(B)** CCR2 expression on monocytes, **(C)** HLADR expression on monocytes, **(D)** Percentage of ASC-speck⁺ CD14^{high}CD16⁻ cells, **(E)** caspase-1 activity measured by FLICA staining, **(F)** lipid peroxidation (LAA) and **(G)** mitochondrial superoxide (MitoSOX) in classical monocytes, **(H)** intracellular glutathione levels in PBMC. **(I)** IL-18 levels were measured in plasma

1 samples. (J-L) Spontaneous *in vitro* IL-1 β , IL-6 and TNF α production by
2 PBMC, respectively. Lines represent median values and interquartile ranges.
3 Closed symbols indicate hospitalized patients (inpatients) and open symbols
4 denote mild disease outpatients. Data were analyzed using the Mann-Whitney
5 test. *P <0.05, ***P <0.01, ****P <0.01; *ns*, not significant.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 **TABLE 1. COVID-19 participant characteristics (% or median values with**
2 **IQR in parenthesis).**

Characteristic	Mild	Moderate-Severe	Recovered
N	31	16	16
Age – y	63 (50-67.5)	62.5 (55.8-69.5)	48.5 (37-57.5)
Female – no. (%)	16 (52)	7 (44)	12 (75)
BMI (Kg/m ²)	31 (28.6-39.5)	28.7 (24-36.4)	31.5 (25.4-48.8)
Race – no. (%)			
White	13 (42)	5 (31)	9 (56)
African American	14 (45)	8 (50)	3 (19)
Other	4 (13)	3 (19)	4 (25)
*ANC (x10 ⁹ cells/L)	3.0 (2.4-4.6)	7.3 (5.1-9.9)	3.6 (3.1-4.9)
*ALC (x10 ⁹ cells/L)	1.3 (1.1-2.0)	1.2 (0.9-1.8)	1.9 (1.4-2.6)
Time from symptoms to lab draw (Days)	9 (6-13.5)	10 (8.8-11.5)	52 (47.3-75.3)
Comorbidities – no. (%)			
Hypertension	18 (58)	12 (75)	8 (50)
Diabetes mellitus	14 (45)	6 (38)	4 (25)
COPD/Asthma	5 (16)	5 (31)	4 (25)
Renal Disease	3 (10)	2 (13)	0 (0)
Treatment – no. (%)			
Remdesivir	6 (19)	11 (69)	4 (25)
Dexamethasone	2 (6)	4 (25)	3 (19)

3
4 * ANC = Absolute neutrophil count, ALC = Absolute leukocyte count.

5

6

7

8

9

10

TABLE 2. Plasma biomarkers measurement in healthy controls (HC) versus COVID-19 patients (median values with IQR in parenthesis).

Biomarker (pg/ml)	HC	COVID-19	p-value
N	13	29	NA
IFN-γ	5.34 (3.2-7.8)	9.17 (4.9-24.6)	0.06
IL-10	0.36 (0.24-0.65)	0.90 (0.60-2.33)	0.003
IL-12p70	0.40 (0.22-0.76)	0.31 (0.19-1.07)	0.94
IL-2	0.43 (0.29-0.47)	0.24 (0.13-0.40)	0.21
IL-6	0.48 (0.24-0.60)	6.07 (1.06-19.1)	<0.001
IL-8	2.41 (1.53-2.89)	4.36 (2.55-6.07)	0.03
TNF-α	1.50 (1.21-1.77)	3.02 (1.67-4.73)	0.002
IL-27	1410 (1095-1733)	2295 (1511-3770)	0.002
CRP (mg/L)	1.81 (1.55-7.45)	83.4 (9.30-187.9)	0.005
SAA (mg/L)	7.85 (3.98-9.96)	230.8 (14.9-404.8)	<0.001
sCD14 (mg/L)	1.36 (1.23-1.66)	1.75 (1.38-2.31)	0.05
IL-6Rα	32960 (30321-37174)	38853 (34737-44826)	0.02
D-dimer (ng/ml)	303 (214-579)	1452 (566-2502)	0.002
Ferritin (ng/ml)	101 (42.7-297)	1100 (173-1650)	0.007

* **p-value** when Mann-Whitney was applied.